Bupropion and hair loss is a concern raised by some patients taking Zyban, the UK-licensed smoking cessation medicine. Bupropion hydrochloride is a norepinephrine–dopamine reuptake inhibitor (NDRI), and whilst alopecia is listed as an uncommon adverse reaction in its UK Summary of Product Characteristics, the direct causal link remains poorly established. Hair thinning during bupropion treatment is often multifactorial, with stress, nutritional deficiencies, and thyroid disorders all capable of mimicking or contributing to drug-related shedding. This article explores what the evidence says, how common the side effect is, and what to do if you notice changes to your hair whilst taking bupropion.

Can Bupropion Cause Hair Loss?

Bupropion lists alopecia as an uncommon adverse reaction in its UK SmPC, but no well-established direct causal mechanism has been confirmed; the association is based on post-marketing surveillance and case reports.

Experiencing these side effects? Our pharmacists can help you navigate them →

Bupropion (available in the UK under the brand name Zyban) is a norepinephrine–dopamine reuptake inhibitor (NDRI). In the UK, it is licensed solely as an aid to smoking cessation; it does not hold a UK marketing authorisation for the treatment of depression, although it is licensed for that indication in some other countries. Like many medicines that act on the central nervous system, bupropion carries a range of potential side effects — and hair loss, known clinically as alopecia, is listed among them in the UK Summary of Product Characteristics (SmPC) for Zyban, albeit as an uncommon adverse reaction.

It is important to note that there is no well-established, direct causal mechanism confirmed in large-scale clinical trials specifically linking bupropion to significant hair loss. The association is based primarily on post-marketing surveillance data and individual case reports submitted to regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA). The UK SmPC for Zyban includes alopecia as an adverse reaction; patients and clinicians should consult the current SmPC (available via the MHRA/EMC) for the precise frequency category, as this may be updated over time.

Patients who notice hair thinning or shedding whilst taking bupropion should not immediately assume the medication is responsible, as many other factors — including the underlying condition being treated, nutritional status, and concurrent stressors — can contribute to hair changes. That said, any new or worsening hair loss during treatment warrants a conversation with a GP or prescribing clinician to properly assess the cause and consider whether any action is needed.

If you think you are experiencing a side effect from bupropion, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. Reporting suspected adverse reactions helps the MHRA monitor the safety of medicines in the UK.

How Common Is Hair Loss as a Side Effect?

Hair loss is not a common or expected outcome of bupropion treatment; for the vast majority of people taking Zyban, noticeable hair shedding will not occur.

Not sure if this is normal? Chat with one of our pharmacists →

The UK SmPC for Zyban (bupropion hydrochloride 150 mg prolonged-release tablets) lists alopecia as an adverse reaction; patients should refer to the current SmPC, available through the MHRA/EMC, for the precise frequency category applicable to the licensed UK product. In general terms, drug-induced hair loss of this type is not considered a common or expected outcome of bupropion treatment, and for the vast majority of people taking Zyban for smoking cessation, noticeable hair loss will not occur.

Post-marketing case reports — which capture adverse events reported by patients and clinicians after a medicine has been approved and is in widespread use — have documented instances of hair thinning and increased shedding in individuals taking bupropion. However, it is important to understand that spontaneous reports of this kind cannot establish causation or determine the true frequency of an adverse effect, as they do not account for confounding variables such as other medications, nutritional deficiencies, or pre-existing hair conditions. The MHRA Yellow Card Scheme collects such reports in the UK, but the data from spontaneous reporting cannot be used to calculate incidence rates or confirm a causal relationship.

Some patients have reported hair regrowth after discontinuing bupropion, which is consistent with a drug-related association in individual cases; however, this is anecdotal and should be interpreted cautiously. Spontaneous resolution of telogen effluvium — a common form of temporary hair shedding triggered by physiological stress — can also occur independently of any medication change, typically improving within six to nine months after the triggering factor is removed. Because of this overlap, it can be genuinely difficult to attribute hair loss solely to bupropion without a thorough clinical assessment. Patients should be reassured that, based on available data, significant hair loss attributable to bupropion alone appears to be uncommon.

Why Some Medicines Affect Hair Growth

Medicines can disrupt the hair growth cycle by pushing follicles into the telogen (resting) phase simultaneously, causing diffuse shedding known as telogen effluvium, which typically resolves once the trigger is removed.

To understand why bupropion might occasionally be associated with hair changes, it helps to understand the normal hair growth cycle. Hair follicles cycle through three phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). Disruption to this cycle — whether caused by illness, nutritional deficiency, hormonal shifts, or certain medications — can push a larger proportion of follicles into the telogen phase simultaneously, resulting in diffuse shedding known as telogen effluvium. This type of shedding typically begins two to three months after the triggering event and, once the trigger is removed or resolves, hair often begins to recover within six to nine months, though individual timelines vary.

Many medicines can trigger this process through a variety of mechanisms. Some drugs interfere directly with cell division in rapidly proliferating follicle cells (as seen with chemotherapy agents), whilst others affect hormonal signalling, alter nutrient absorption, or induce physiological stress responses that indirectly disrupt the hair cycle. Bupropion's precise mechanism in relation to hair loss — if indeed it is directly causative — is not fully understood. Its primary pharmacological action involves inhibiting the reuptake of norepinephrine and dopamine in the brain, and it has been theorised that alterations in these neurotransmitter pathways could, in some individuals, influence peripheral processes including hair follicle activity, though this remains speculative.

Other drug classes associated with hair loss include:

• Anticoagulants (e.g., warfarin, heparin)

• Antithyroid medications

• Retinoids (e.g., isotretinoin)

• Beta-blockers

• Antiepileptics (e.g., valproate)

• Lithium

• Certain antidepressants (various classes have been implicated in case reports and observational data)

• ACE inhibitors and interferons

Understanding that drug-induced hair loss is often temporary and may resolve following dose adjustment or discontinuation — under medical supervision — can be reassuring for patients who are concerned about this side effect. For further information on telogen effluvium, the British Association of Dermatologists and NICE Clinical Knowledge Summaries (CKS) provide accessible patient-facing resources.

What to Do If You Notice Hair Thinning on Bupropion

Speak to your GP before making any medication changes; first-line investigations include full blood count, ferritin, and thyroid function tests to exclude common treatable causes.

If you begin to notice increased hair shedding, thinning, or changes in hair texture whilst taking bupropion, the first and most important step is to speak with your GP or prescribing clinician before making any changes to your medication. Stopping bupropion abruptly — particularly if it is being used for smoking cessation — risks relapse to smoking and associated health harms, and should never be done without medical guidance.

Your clinician will likely begin by taking a thorough history and examination. In line with UK primary care practice (NICE CKS), the first-line investigations to consider include:

• Full blood count (FBC) — to check for anaemia

• Ferritin and iron studies — low iron stores are a common and treatable cause of diffuse hair thinning

• Thyroid function tests (TFTs) — both hypothyroidism and hyperthyroidism are well-recognised causes of hair loss

Further tests — such as vitamin B12, vitamin D, zinc, coeliac serology, or a hormonal profile (for example, to assess for polycystic ovary syndrome in women) — should be guided by the clinical history and examination findings rather than ordered routinely.

If investigations reveal an alternative cause, this can be addressed directly. If bupropion is considered the likely contributor and the hair loss is distressing or significant, your clinician may discuss options such as dose reduction or switching to an alternative medication, carefully weighing the benefits of your current treatment against the side effect burden.

In the meantime, gentle hair care practices — avoiding excessive heat styling, tight hairstyles, and harsh chemical treatments — can help minimise further mechanical damage.

Red flags that warrant prompt referral to a dermatologist include:

• Rapid or progressive hair loss

• Scalp inflammation, pain, redness, or scarring (which may suggest scarring alopecia requiring urgent assessment)

• Patchy hair loss with scalp scaling or broken hairs (which may indicate tinea capitis, particularly in children — this requires prompt treatment and specialist input)

• Diagnostic uncertainty after initial assessment

Referral to a dermatologist is appropriate in these circumstances, or if hair loss is severe or persistent despite addressing identifiable causes.

Other Factors That May Contribute to Hair Loss

Hair loss is multifactorial; stress, iron deficiency, thyroid disorders, androgenetic alopecia, and concurrent medications can all independently cause thinning and must be assessed before attributing hair loss to bupropion.

It is essential to consider that hair loss is a multifactorial condition, and in many cases where a patient taking bupropion notices thinning, the medication may not be the primary — or even a contributing — cause. Several common conditions and circumstances can independently trigger or worsen hair shedding, and these must be carefully evaluated before attributing the problem to any specific drug.

Psychological and physiological stress is one of the most frequent triggers of telogen effluvium. Given that bupropion is often prescribed during periods of significant lifestyle change — such as quitting smoking — the underlying stress associated with these experiences may itself be responsible for hair changes. Similarly, nutritional deficiencies, particularly of iron, zinc, and protein, are recognised causes of diffuse hair thinning. Biotin deficiency is rare in the UK in the absence of specific risk factors (such as certain gastrointestinal conditions or prolonged parenteral nutrition) and should not be assumed as a routine cause; routine biotin supplementation is not recommended without evidence of deficiency. It is also worth noting that high-dose biotin supplements can interfere with certain laboratory assays and should be disclosed to your clinician before blood tests are taken.

Thyroid disorders, both hypothyroidism and hyperthyroidism, are strongly associated with hair loss and are relatively common, particularly in women. Androgenetic alopecia (pattern hair loss) is the most prevalent form of hair loss overall and follows a predictable, gradual pattern that may simply become more noticeable during a period when a patient is paying closer attention to their health. Postpartum hair loss and autoimmune conditions such as alopecia areata are further possibilities that require distinct management approaches.

Scalp infections such as tinea capitis can also cause hair loss and require prompt assessment and treatment, particularly in children, where specialist referral may be needed.

Certain other medications taken concurrently with bupropion — including mood stabilisers, antihypertensives, or hormonal contraceptives — may also contribute to hair changes. A holistic review of all prescribed and over-the-counter medicines is therefore an important part of any assessment.

Ultimately, a thorough clinical evaluation — guided by NICE CKS and NHS primary care pathways — is the only reliable way to identify the true cause and guide appropriate treatment. The NHS Hair Loss patient information page and NICE CKS resources on alopecia provide further guidance for patients and clinicians.

Frequently Asked Questions